Matthew Norkunas

Chief Financial & Accounting Officer at Generation Bio Co.

Matthew Norkunas

Matthew Norkunas

Chief Financial & Accounting Officer at Generation Bio Co.

Biography

Currently, Matthew Norkunas holds the position of Chief Financial & Accounting Officer of Generation Bio Co. In his past career he held the position of Chief Financial Officer for SomaLogic, Inc. and Senior Analyst at Marsico Capital Management LLC. Dr. Norkunas received an undergraduate degree from St. Mary's College (Maryland), a doctorate from the University of Maryland and an MBA from Columbia Business School.

Overview
Career Highlights

Generation Bio Co.
SomaLogic, Inc.

RelSci Relationships

128

Birthday

1978

Age

42

Relationships
RelSci Relationships are individuals Matthew Norkunas likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Generation Bio Co.

Relationship likelihood: Strong

President & Chief Executive Officer at Generation Bio Co.

Relationship likelihood: Strong

Co-Founder at Disarm Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Generation Bio Co.

Relationship likelihood: Strong

Founder at SomaLogic, Inc.

Relationship likelihood: Strong

Executive Director, Communications at SomaLogic, Inc.

Relationship likelihood: Strong

Chief Commercial Officer at SomaLogic, Inc.

Relationship likelihood: Average

Chief Informatics Officer at SomaLogic, Inc.

Relationship likelihood: Average

Chief Medical Officer at SomaLogic, Inc.

Relationship likelihood: Average

Chief Science Officer at SomaLogic, Inc.

Relationship likelihood: Average

Paths to Matthew Norkunas
Potential Connections via
Relationship Science
You
Matthew Norkunas
Chief Financial & Accounting Officer at Generation Bio Co.
Education
Class of 2004

The University of Maryland, College Park is a public research university, the flagship campus of the University System of Maryland, and the original 1862 land-grant institution in the State. The University of Maryland is committed to achieving excellence as the State’s primary center of research and graduate education and the institution of choice for undergraduate students of exceptional ability and promise. The University creates and applies knowledge for the benefit of the economy and culture of the State, the region, the nation, and beyond. As the flagship of the University System of Maryland, the University shares its research, educational, cultural, and technological strengths with businesses, government, and other educational institutions. The University counts among its greatest strengths -- and a major component of its excellence -- the diversity of its faculty, students, and staff. The University of Maryland, College Park is committed to equal educational opportunity and strives to hire a diverse faculty and staff of exceptional achievement through affirmative actions, to celebrate diversity in all of its programs and activities, and to recruit and retain qualified graduate and undergraduate minority students.

Class of 1999

St Mary's College of Maryland is a school in Lexington Park.

Columbia Business School (CBS) is the business school of Columbia University in Manhattan, New York City. It was established in 1916 to provide business training and professional preparation for undergraduate and graduate Columbia University students. It is one of six Ivy League business schools and its admission process is among the most selective of top business schools.

Career History
Chief Financial & Accounting Officer
2020 - Current

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Chief Financial Officer
2016 - 2020

SomaLogic, Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at your institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO.

Senior Analyst
2012 - Prior

MCM primarily uses top-down and bottom-up fundamental methods of analysis in implementing its strategies. While they invest primarily in growth equity securities for clients, client accounts also may hold a variety of other securities and investments potentially including fixed income if desired. The firm does not does not generally manage portfolios based on alternative strategies such as asset allocation, long-short, risk-neutral, absolute return, or similar strategies. MCM doesn’t use quantitative filters or screens or optimization techniques in portfolio construction, or target tracking error levels, standard deviations, or other such metrics.

Transactions
Details Hidden

SomaLogic, Inc. raised money in a private placement transaction

Details Hidden

SomaLogic, Inc. raised money in a private placement transaction

Details Hidden

SomaLogic, Inc. raised money in a private placement transaction

Other Affiliations

Matthew Norkunas is affiliated with Generation Bio Co., SomaLogic, Inc., Marsico Capital Management LLC

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Matthew Norkunas. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Matthew Norkunas's profile does not indicate a business or promotional relationship of any kind between RelSci and Matthew Norkunas.